Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De Sells 7,373 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 7,373 shares of the business’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total transaction of $67,389.22. Following the sale, the executive vice president now directly owns 79,460 shares in the company, valued at $726,264.40. This trade represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Verneuil Vanina De also recently made the following trade(s):

• On Monday, December 2nd, Verneuil Vanina De sold 76 shares of Vir Biotechnology stock. The stock was sold at an average price of $8.22, for a total value of $624.72.

Vir Biotechnology Price Performance

VIR opened at $8.11 on Friday. The firm has a fifty day moving average price of $9.44 and a 200 day moving average price of $8.50. Vir Biotechnology, Inc. has a 1 year low of $6.56 and a 1 year high of $14.45. The stock has a market cap of $1.12 billion, a P/E ratio of -2.07 and a beta of 0.63.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. Equities analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, January 31st. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Barclays cut their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Leerink Partners boosted their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.83.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds have recently bought and sold shares of the business. State Street Corp increased its position in shares of Vir Biotechnology by 10.4% in the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after buying an additional 530,645 shares in the last quarter. Geode Capital Management LLC increased its holdings in Vir Biotechnology by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company’s stock worth $16,127,000 after acquiring an additional 7,827 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Vir Biotechnology by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company’s stock worth $14,059,000 after acquiring an additional 703,360 shares during the period. Millennium Management LLC lifted its holdings in Vir Biotechnology by 55.3% during the fourth quarter. Millennium Management LLC now owns 1,715,083 shares of the company’s stock valued at $12,589,000 after purchasing an additional 610,367 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Vir Biotechnology by 10.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company’s stock valued at $9,194,000 after purchasing an additional 118,379 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).